A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02117024. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatucel-L (HS-110) in Combination With Low Dose (Metronomic) Cyclophosphamide Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Adenocarcinoma After Failure of Two or Three Previous Treatment Regimens for Advanced Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Determine whether viagenpumatucel-L combined with low-dose cyclophosphamide prolongs survival in patients with NSCLC who failed 2 or 3 prior lines of therapy for incurable or metastatic disease compared with chemotherapy alone.
Study identification
- NCT ID
- NCT02117024
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Interventions
- Viagenpumatucel-L Drug
- Metronomic Cyclophosphamide Drug
- Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2014 (Type not available)
- Primary completion
- Dec 2017 (Actual)
- Completion
- Apr 2018 (Actual)
- Last update posted
- Feb 5, 2020
2014 – 2018
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| University of California San Diego | La Jolla | California | 92093 | — |
| University of California at Los Angeles | Los Angeles | California | 90029 | — |
| University of California Davis | Sacramento | California | 95817 | — |
| Georgia Regents University | Augusta | Georgia | 30912 | — |
| University of Maryland Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| University of Massachusetts | Worcester | Massachusetts | 01655 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| SUNY Syracuse | Syracuse | New York | 13210 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Providence Portland Medical Center- Providence Lung Cancer Clinic | Portland | Oregon | 97213 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Texas Oncology PA Texas Cancer Center | Abilene | Texas | 79606 | — |
| Mary Crowley Cancer Center | Dallas | Texas | 75201 | — |
| Cancer Care Northwest | Spokane | Washington | 99216 | — |
| Aurora Research Institute | Green Bay | Wisconsin | 54311 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02117024, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2020 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02117024 live on ClinicalTrials.gov.